🚀 CSPC Pharmaceutical Group Receives FDA Approval for Clinical Trials of SYH2082 Injection
#CSPCPharmaceuticalGroup #FDAApproval #ClinicalTrials #SYH2082 #GLP1GIPReceptor #DualBiasedAgonist #PeptideInjection #WeightManagement #Obesity #Overweight #Type2Diabetes #BloodGlucoseControl
CSPC Pharmaceutical Group announced that its GLP-1/GIP receptor dual-biased agonist peptide long-acting injection, SYH2082, has received approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the United States. According to Jin10, the approved clinical indication is for weight management in individuals who are obese or overweight with at least one weight-related comorbidity. Additionally, SYH2082 has the potential to improve blood glucose control in adults with type 2 diabetes mellitus (T2DM), offering additional clinical benefits.#CSPCPharmaceuticalGroup #FDAApproval #ClinicalTrials #SYH2082 #GLP1GIPReceptor #DualBiasedAgonist #PeptideInjection #WeightManagement #Obesity #Overweight #Type2Diabetes #BloodGlucoseControl
🚀 Morgan Stanley Adjusts Global Stock and U.S. Treasury Ratings
#MorganStanley #GlobalStockRating #USTreasuries #OilSupplyDisruptions #RiskAssets #Overweight #EqualWeight
Morgan Stanley has revised its global stock rating from overweight to equal weight. According to ChainCatcher, the firm has also upgraded its ratings for U.S. Treasuries and cash from equal weight to overweight. The institution highlighted the uncertainty surrounding the scale and duration of oil supply disruptions, indicating that the trajectory of risk assets has become increasingly asymmetric.#MorganStanley #GlobalStockRating #USTreasuries #OilSupplyDisruptions #RiskAssets #Overweight #EqualWeight